Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial.

Lüthi H, Lengsfeld S, Burkard T, Meienberg A, Jeanloz N, Vukajlovic T, Bologna K, Steinmetz M, Bathelt C, Sailer CO, Laager M, Vogt DR and 9 more

Show all authors

Hemkens LG, Speich B, Urwyler SA, Kühne J, Baur F, Lutz LN, Erlanger TE, Christ-Crain M, Winzeler B

EClinicalMedicine9 Feb 2024Cited by 36 (Europe PMC)

PMID38371479PMCIDPMC10873660DOI10.1016/j.eclinm.2024.102429PepBankPUB-38371479

Read at source PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In smokers, abstinence at 24 weeks was 43% with dulaglutide and 41% with placebo.
In plain wordsIn smokers, abstinence was 43% with dulaglutide and 41% with placebo at 24 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedAbstinence at 24 weeks
Study
n = 255
Comparator
Placebo
Analysis
Primary
Outcome group
Addiction, withdrawal and alcohol intake · Whole body
Studied dose
1.5 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Abstinence rate
43%
Dulaglutide group at 24 weeks (54/127)
Abstinence rate
41%
Placebo group at 24 weeks (52/128)
Source sentences
Summary
These abstinence rates declined to 43% (54/127) and 41% (52/128), respectively, after 24 weeks and to 32% (41/127) and 32% (41/128), respectively, after 52 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
Of the 255 participants who were randomly assigned between June 22, 2017 and December 3, 2020, 63% (80/127) (dulaglutide group) and 65% (83/128) (placebo group) were abstinent after 12 weeks.
Summary · context
This single-centre, randomised, double-blind, placebo-controlled, parallel group trial was done at the University Hospital Basel in Switzerland.
Summary · context
We randomly assigned (1:1) individuals with at least a moderate nicotine dependence willing to quit smoking to either a 12-week treatment with dulaglutide 1.5 mg or placebo subcutaneously once weekly
Report a problemFND-3837147902
02HumanRandomized controlled trialEfficacy outcome
In smokers, abstinence at 52 weeks was 32% in both dulaglutide and placebo groups.
In plain wordsIn smokers, abstinence was 32% with both dulaglutide and placebo at 52 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedAbstinence at 52 weeks
Study
n = 255
Comparator
Placebo
Analysis
Primary
Outcome group
Addiction, withdrawal and alcohol intake · Whole body
Studied dose
1.5 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Abstinence rate
32%
Dulaglutide group at 52 weeks (41/127)
Abstinence rate
32%
Placebo group at 52 weeks (41/128)
Source sentences
Summary
These abstinence rates declined to 43% (54/127) and 41% (52/128), respectively, after 24 weeks and to 32% (41/127) and 32% (41/128), respectively, after 52 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
Of the 255 participants who were randomly assigned between June 22, 2017 and December 3, 2020, 63% (80/127) (dulaglutide group) and 65% (83/128) (placebo group) were abstinent after 12 weeks.
Summary · context
This single-centre, randomised, double-blind, placebo-controlled, parallel group trial was done at the University Hospital Basel in Switzerland.
Summary · context
We randomly assigned (1:1) individuals with at least a moderate nicotine dependence willing to quit smoking to either a 12-week treatment with dulaglutide 1.5 mg or placebo subcutaneously once weekly
Report a problemFND-3837147903
03HumanRandomized controlled trialEfficacy outcome
In smokers, weight increased in both groups at week 24, with a dulaglutide-placebo difference whose confidence interval included zero.
In plain wordsIn smokers, weight increased with both treatments at week 24, without a clear difference between dulaglutide and placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedWeight change at 24 weeks
Study
n = 255
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Median weight change from baseline at week 24
1.5 kg
dulaglutide
Median weight change from baseline at week 24
3 kg
placebo
Baseline-adjusted difference in weight change
−1 kg
dulaglutide versus placebo, week 24
97.5% CI of difference in weight change
−2.16 to 0.16 kg
dulaglutide versus placebo, week 24
Source sentences
Summary
However, at week 24, increases in weight from baseline were observed in both groups (median, interquartile range [IQR]: dulaglutide: +1.5 kg, [-0.4, 4.1], placebo: +3.0 kg, [0.6, 4.6], baseline-adjusted difference in weight change -1.0 kg (97.5% CI [-2.16, 0.16]))
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, double-blind, placebo-controlled, parallel group trial was done at the University Hospital Basel in Switzerland.
Summary · context
We randomly assigned (1:1) individuals with at least a moderate nicotine dependence willing to quit smoking to either a 12-week treatment with dulaglutide 1.5 mg or placebo subcutaneously once weekly
Report a problemFND-3837147905
04HumanRandomized controlled trialEfficacy outcome
In smokers, weight gain at week 52 was similar after dulaglutide and placebo.
In plain wordsIn smokers, weight gain at week 52 was similar after dulaglutide and placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeWeight change at 52 weeks
Study
n = 255
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Median weight change from baseline at week 52
2.8 kg
dulaglutide
Median weight change from baseline at week 52
3.1 kg
placebo
Baseline-adjusted difference in weight change
−0.35 kg
dulaglutide versus placebo, week 52
95% CI of difference in weight change
−1.72 to 1.01 kg
dulaglutide versus placebo, week 52
Source sentences
Summary
and at week 52 the groups showed similar weight gain (median, IQR: dulaglutide: +2.8 kg [-0.4, 4.7], placebo: +3.1 kg [-0.4, 6.0], baseline-adjusted difference in weight change: -0.35 kg (95% CI [-1.72, 1.01])).
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, double-blind, placebo-controlled, parallel group trial was done at the University Hospital Basel in Switzerland.
Summary · context
We randomly assigned (1:1) individuals with at least a moderate nicotine dependence willing to quit smoking to either a 12-week treatment with dulaglutide 1.5 mg or placebo subcutaneously once weekly
Report a problemFND-3837147906
05HumanRandomized controlled trialEfficacy outcome
In smokers, abstinence at 12 weeks was 63% with dulaglutide and 65% with placebo.
In plain wordsIn smokers, abstinence was 63% with dulaglutide and 65% with placebo at 12 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedAbstinence at 12 weeks
Study
n = 255
Comparator
Placebo
Outcome group
Addiction, withdrawal and alcohol intake · Whole body
Studied dose
1.5 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Abstinence rate
63%
Dulaglutide group at 12 weeks (80/127)
Abstinence rate
65%
Placebo group at 12 weeks (83/128)
Source sentences
Summary
Of the 255 participants who were randomly assigned between June 22, 2017 and December 3, 2020, 63% (80/127) (dulaglutide group) and 65% (83/128) (placebo group) were abstinent after 12 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, double-blind, placebo-controlled, parallel group trial was done at the University Hospital Basel in Switzerland.
Summary · context
We randomly assigned (1:1) individuals with at least a moderate nicotine dependence willing to quit smoking to either a 12-week treatment with dulaglutide 1.5 mg or placebo subcutaneously once weekly
Report a problemFND-3837147901
06HumanRandomized controlled trialEfficacy outcome
In smokers, dulaglutide prevented weight gain compared with placebo at 12 weeks.
In plain wordsIn smokers, dulaglutide prevented weight gain compared with placebo at 12 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight change at 12 weeks
Study
n = 255
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Weight change
−1 kg
Dulaglutide group at 12 weeks, SD 2.7
Weight change
1.9 kg
Placebo group at 12 weeks, SD 2.4
Source sentences
Summary
Post-cessation weight gain was prevented in the dulaglutide group (-1.0 kg, standard deviation [SD] 2.7) as opposed to the placebo group (+1.9 kg, SD 2.4) after 12 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, double-blind, placebo-controlled, parallel group trial was done at the University Hospital Basel in Switzerland.
Summary · context
We randomly assigned (1:1) individuals with at least a moderate nicotine dependence willing to quit smoking to either a 12-week treatment with dulaglutide 1.5 mg or placebo subcutaneously once weekly
Report a problemFND-3837147904
07HumanRandomized controlled trialSafety outcome
During follow-up, treatment-unrelated adverse events numbered 51 with dulaglutide and 48 with placebo.
In plain wordsDuring follow-up, treatment-unrelated adverse events numbered 51 with dulaglutide and 48 with placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedTreatment-unrelated adverse events
Study
n = 255
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
1.5 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Treatment-unrelated adverse events
51 events
dulaglutide, week 12 to 52
Treatment-unrelated adverse events
48 events
placebo, week 12 to 52
Treatment-unrelated adverse events
51%
dulaglutide, week 12 to 52
Treatment-unrelated adverse events
48%
placebo, week 12 to 52
Source sentences
Summary
In the follow-up period (week 12 to week 52) 51 (51%) and 48 (48%) treatment-unrelated adverse events were recorded in the dulaglutide and the placebo group, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, double-blind, placebo-controlled, parallel group trial was done at the University Hospital Basel in Switzerland.
Summary · context
We randomly assigned (1:1) individuals with at least a moderate nicotine dependence willing to quit smoking to either a 12-week treatment with dulaglutide 1.5 mg or placebo subcutaneously once weekly
Report a problemFND-3837147907
08HumanRandomized controlled trialSafety outcome
In the smoking trial, no treatment-related serious adverse events occurred with dulaglutide or placebo.
In plain wordsIn the smoking trial, neither dulaglutide nor placebo had treatment-related serious adverse events.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedTreatment-related serious adverse events
Study
n = 255
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
1.5 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
No treatment-related serious adverse events or deaths occurred.
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, double-blind, placebo-controlled, parallel group trial was done at the University Hospital Basel in Switzerland.
Summary · context
We randomly assigned (1:1) individuals with at least a moderate nicotine dependence willing to quit smoking to either a 12-week treatment with dulaglutide 1.5 mg or placebo subcutaneously once weekly
Report a problemFND-3837147908
09HumanRandomized controlled trialSafety outcome
In the smoking trial, no treatment-related deaths occurred.
In plain wordsIn the smoking trial, no treatment-related deaths occurred.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedDeaths
Study
n = 255
Comparator
Placebo
Outcome group
Mortality · Whole body
Studied dose
1.5 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
No treatment-related serious adverse events or deaths occurred.
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre, randomised, double-blind, placebo-controlled, parallel group trial was done at the University Hospital Basel in Switzerland.
Summary · context
We randomly assigned (1:1) individuals with at least a moderate nicotine dependence willing to quit smoking to either a 12-week treatment with dulaglutide 1.5 mg or placebo subcutaneously once weekly
Report a problemFND-3837147909

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT03204396

Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues

University Hospital, Basel, Switzerlandn = 25626 Jun 2017 to 30 Aug 2022

Glucagon-like Peptide-1 · Smoking Cessation · Weight Change, Body · Craving

Trial page ClinicalTrials.govUpdated 13 Sept 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.